Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 72Liver Disease Diagnosis and TreatmentFatty Acid Research and HealthAquaculture Nutrition and Growth

The DOI matches its Crossref record, with a small difference in title or year; 22 of the 22 references it cites were found in a registry or an index.

Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials

Chen, Lian-hui, Wang, Yong-fen, Xu, Qing-hong, Chen, Shan-Shan·2018·Clinical Nutrition
DOI 10.1016/j.clnu.2016.12.009
Open this paper in CoChat — free account

Abstract

Background The most typical chronic liver disease in children and adolescents is non-alcoholic fatty liver disease (NAFLD). The dietary addition of ω-3 polyunsaturated fatty acids (PUFAs) provides a promising therapy for children with NAFLD due to its convenience and safety; however, several studies suggested contradictory results for PUFA supplementation in children. Hence, we performed a systematic review and meta-analysis to evaluate the effectiveness of PUFA supplementation in children with NAFLD. Methods Published randomized controlled trials (RCTs) that evaluated the effectiveness of the dietary addition of PUFA in children with NAFLD were considered. The primary result was the alteration in hepatic steatosis grade on ultrasound after treatment. The secondary outcomes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), C-reactive protein (CRP) and components of metabolic syndrome. Predefined sensitivity analysis was also performed to explore possible explanations for heterogeneity in the evaluations. Results In total, 4 studies with 263 subjects were identified. PUFA supplementation was associated with significantly improved hepatic steatosis grade on ultrasound (risk difference: 25%, 95% CI: 12-38%), without heterogeneity (P = 0.27, I 2 = 24%). Sensitivity analysis confirmed the robustness of our findings. PUFA supplementation could decrease AST levels after 6 months, but could only reduce ALT levels after 12 months. PUFA did not have a significant effect on most components of metabolic syndrome and the CRP level. Conclusion ω-3 PUFA supplementation can improve liver steatosis and liver functions, and it is a potential food supplementation to treat NAFLD in children.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.clnu.2016.12.009

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 72

Metadata

Authors
Chen, L.-H., Wang, Y.-F., Xu, Q.-H., & Chen, S.-S.
Affiliations
  • Second Affiliated Hospital of Fujian Medical University (CN)
  • Fujian Medical University (CN)
Venue
Clinical Nutrition
Publisher
Elsevier BV
Published
2018-04
Volume
37
Issue
2
Pages
516-521
ISSN
0261-5614 (ISSN-L)
DOI
10.1016/j.clnu.2016.12.009
OpenAlex
W2567124592
Cited by
72
References
22
Citations by year
2026: 3 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 11
FWCI
1.13
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Clinical Nutrition (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
Keywords
omega-3 fatty acids, polyunsaturated fatty acids, non-alcoholic fatty liver disease, pediatric NAFLD, dietary supplementation, hepatic steatosis, alanine aminotransferase, aspartate aminotransferase, C-reactive protein, metabolic syndrome, liver function
MeSH terms
Adolescent, Child, Humans, Fatty Acids, Omega-3, Randomized Controlled Trials as Topic, Treatment Outcome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.